Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.

Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.

Vedolizumab (VDZ) is a therapeutic monoclonal antibody approved for the treatment of inflammatory bowel diseases (IBD). VDZ selectively binds to the α4β7 integrin and blocks trafficking of a specific subset of gastrointestinal-homing T-lymphocytes to inflamed tissue. Although VDZ has shown promising...

Full description

Bibliographic Details
Main Authors: Rossana Domenis, Marco Marino, Adriana Cifù, Giulia Scardino, Francesco Curcio, Martina Fabris
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0242342

Similar Items

Similar Items